Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Tech Monitor.
Press releases published on May 30, 2025

Blue and Red BV Joins Forces with ScreenCom BV to Create Integrated Workspace Technology Leader
AMSTERDAM, May 30, 2025 (GLOBE NEWSWIRE) -- Blue and Red BV, a specialist in digital signage and workspace management technology, today announced the successful completion of its strategic merger with ScreenCom BV, a leading provider of enterprise digital …

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, …

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of …

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
RESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data which highlights the reduction in the percentage of days with hereditary angioedema (HAE) symptoms among young children …

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in …

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, Chief Executive Officer, will present at …

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant …

Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will participate in a …

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million milestone payment to be received from …

XDC Network Partners with Bitso Business to Power Cross-Border Payments from the U.S. to Mexico
Mexico City, Mexico, May 30, 2025 (GLOBE NEWSWIRE) -- The XDC Network, a leading blockchain platform for real-world finance, is proud to announce a strategic partnership with Bitso Business - the B2B arm of Bitso that provides infrastructure for efficient …

Best VPN for Streaming (2025): IPVanish Recognized as Top Streaming VPN by Software Experts
NEW YORK CITY, May 30, 2025 (GLOBE NEWSWIRE) -- Software Experts has recognized IPVanish as the Best VPN for Streaming in 2025, citing its strong performance across speed, server coverage, privacy features, and usability. The review highlights IPVanish’s …

Aurora Mobile's GPTBots.ai Welcomes the Enhanced DeepSeek-R1-0528 Model to Power Enterprise AI Solutions
SHENZHEN, China, May 30, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services in China, today announced the integration of newly updated …

ScreenCom BV Expands Digital Signage Ecosystem Through Strategic Merger with Blue and Red BV
AMSTERDAM, May 30, 2025 (GLOBE NEWSWIRE) -- ScreenCom BV, a leading provider of enterprise digital signage solutions, today announced the successful completion of its merger with Blue and Red BV, a specialist in digital signage and workspace management …

Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 months Survival has currently reached plateau, with 34% (7/20) of patients still alive 80% of patients treated with …

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided …

Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO
L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’étude AERIFY-1 a atteint son objectif principal, à savoir une réduction statistiquement significative des exacerbations modérées ou sévères chez …

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit AERIFY-2, a second Phase 3 trial, did …

Quantum eMotion Announces Brokered LIFE Financing of C$6,000,000
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum eMotion Corp. (“QeM” or the “Corporation”) (TSX.V: QNC; OTCQB: QNCCF) is pleased to announce a best efforts brokered …

Miningcoop Launches One of the Top and Most Profitable Bitcoin & Dogecoin Cloud Mining Services with Instant Setup and Daily Earnings
London, UK, May 29, 2025 (GLOBE NEWSWIRE) -- According to the latest April 2025 report by Statista, global Bitcoin mining revenue is expected to surpass $50 billion this year, setting a new all-time high. Rising energy costs, expensive mining hardware, and …